AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) – Investment analysts at Jefferies Group issued their FY2022 earnings per share estimates for shares of AcelRx Pharmaceuticals in a research report issued to clients and investors on Tuesday. Jefferies Group analyst M. Andrews forecasts that the specialty pharmaceutical company will post earnings of ($0.25) per share for the year.

Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. AcelRx Pharmaceuticals has a consensus rating of “Hold” and an average target price of $6.21.

Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) traded up $0.02 during trading hours on Wednesday, hitting $1.73. 238,000 shares of the stock traded hands, compared to its average volume of 391,073. The stock has a market cap of $88.09, a P/E ratio of -1.56 and a beta of 2.64. The company has a quick ratio of 4.71, a current ratio of 4.78 and a debt-to-equity ratio of -0.43. AcelRx Pharmaceuticals has a twelve month low of $1.55 and a twelve month high of $5.75.

Institutional investors have recently made changes to their positions in the company. Perennial Advisors LLC acquired a new position in shares of AcelRx Pharmaceuticals in the 3rd quarter valued at $138,000. Virtu Financial LLC acquired a new position in shares of AcelRx Pharmaceuticals in the 4th quarter valued at $120,000. Geller Family Office Services LLC acquired a new position in shares of AcelRx Pharmaceuticals in the 3rd quarter valued at $460,000. Virtu KCG Holdings LLC increased its holdings in shares of AcelRx Pharmaceuticals by 600.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after acquiring an additional 101,742 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new position in shares of AcelRx Pharmaceuticals in the 2nd quarter valued at $530,000. 13.61% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://theolympiareport.com/2018/02/14/brokers-offer-predictions-for-acelrx-pharmaceuticals-incs-fy2022-earnings-acrx.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.